Bruce Bender
Concepts (393)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 89 | 2024 | 2298 | 10.600 |
Why?
| | Patient Compliance | 29 | 2024 | 581 | 4.690 |
Why?
| | Anti-Asthmatic Agents | 20 | 2022 | 397 | 4.100 |
Why?
| | Medication Adherence | 21 | 2024 | 467 | 3.470 |
Why?
| | Adrenal Cortex Hormones | 22 | 2022 | 565 | 2.160 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 10 | 2023 | 1042 | 1.880 |
Why?
| | Telemedicine | 9 | 2024 | 862 | 1.770 |
Why?
| | Food Hypersensitivity | 4 | 2020 | 183 | 1.660 |
Why?
| | Bronchodilator Agents | 8 | 2020 | 252 | 1.610 |
Why?
| | Dermatitis, Atopic | 8 | 2018 | 329 | 1.470 |
Why?
| | Electronic Mail | 2 | 2021 | 64 | 1.330 |
Why?
| | Adrenergic beta-Agonists | 3 | 2020 | 134 | 1.200 |
Why?
| | Patient Education as Topic | 10 | 2021 | 766 | 1.160 |
Why?
| | Health Personnel | 4 | 2021 | 711 | 1.130 |
Why?
| | Self Care | 8 | 2021 | 380 | 1.110 |
Why?
| | Health Communication | 2 | 2018 | 43 | 1.110 |
Why?
| | Speech Recognition Software | 2 | 2018 | 12 | 1.060 |
Why?
| | Humans | 130 | 2024 | 137782 | 1.020 |
Why?
| | Rhinitis, Allergic | 2 | 2018 | 40 | 1.000 |
Why?
| | Administration, Inhalation | 19 | 2023 | 688 | 0.910 |
Why?
| | Child | 53 | 2024 | 21989 | 0.890 |
Why?
| | Anti-Allergic Agents | 4 | 2018 | 46 | 0.870 |
Why?
| | Disease Management | 3 | 2018 | 629 | 0.850 |
Why?
| | Stress, Psychological | 5 | 2018 | 1108 | 0.840 |
Why?
| | Monitoring, Physiologic | 4 | 2019 | 283 | 0.840 |
Why?
| | Reminder Systems | 4 | 2024 | 169 | 0.830 |
Why?
| | Metered Dose Inhalers | 5 | 2012 | 16 | 0.820 |
Why?
| | Glucocorticoids | 4 | 2016 | 596 | 0.820 |
Why?
| | Bullying | 2 | 2016 | 39 | 0.800 |
Why?
| | Hypersensitivity | 4 | 2024 | 257 | 0.800 |
Why?
| | Cell Phone | 2 | 2021 | 76 | 0.760 |
Why?
| | Parents | 12 | 2022 | 1350 | 0.760 |
Why?
| | Communication | 3 | 2021 | 879 | 0.740 |
Why?
| | Personnel Management | 1 | 2021 | 18 | 0.710 |
Why?
| | Text Messaging | 2 | 2020 | 157 | 0.700 |
Why?
| | Sleep Wake Disorders | 7 | 2016 | 290 | 0.690 |
Why?
| | Rhinitis, Allergic, Seasonal | 3 | 2005 | 29 | 0.690 |
Why?
| | Telecommunications | 2 | 2018 | 21 | 0.680 |
Why?
| | Tobacco Products | 1 | 2022 | 138 | 0.670 |
Why?
| | Delivery of Health Care | 5 | 2023 | 951 | 0.650 |
Why?
| | Electronic Health Records | 3 | 2024 | 1070 | 0.630 |
Why?
| | Research Design | 4 | 2023 | 1139 | 0.630 |
Why?
| | Self-Management | 2 | 2019 | 182 | 0.620 |
Why?
| | Nurse-Patient Relations | 1 | 2020 | 70 | 0.620 |
Why?
| | Treatment Adherence and Compliance | 1 | 2019 | 26 | 0.610 |
Why?
| | Minority Groups | 5 | 2017 | 266 | 0.610 |
Why?
| | Biological Products | 1 | 2022 | 219 | 0.610 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 2 | 2019 | 37 | 0.590 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 2 | 2015 | 104 | 0.590 |
Why?
| | Organizational Culture | 1 | 2020 | 152 | 0.590 |
Why?
| | Prescription Drug Overuse | 1 | 2018 | 13 | 0.580 |
Why?
| | Workload | 1 | 2020 | 167 | 0.580 |
Why?
| | Quality of Life | 12 | 2020 | 2894 | 0.580 |
Why?
| | Health Behavior | 3 | 2013 | 762 | 0.570 |
Why?
| | Motivation | 3 | 2020 | 570 | 0.570 |
Why?
| | Behavioral Medicine | 1 | 2018 | 37 | 0.560 |
Why?
| | Urticaria | 1 | 2018 | 39 | 0.550 |
Why?
| | Health Promotion | 2 | 2014 | 742 | 0.550 |
Why?
| | Substance-Related Disorders | 2 | 2022 | 1083 | 0.540 |
Why?
| | Physician-Patient Relations | 5 | 2014 | 558 | 0.530 |
Why?
| | Androstadienes | 3 | 2008 | 107 | 0.530 |
Why?
| | Fluticasone-Salmeterol Drug Combination | 1 | 2016 | 12 | 0.520 |
Why?
| | Tobacco Smoke Pollution | 2 | 2014 | 261 | 0.520 |
Why?
| | Laryngeal Diseases | 1 | 2016 | 31 | 0.510 |
Why?
| | Spirometry | 5 | 2021 | 282 | 0.510 |
Why?
| | Male | 56 | 2024 | 67906 | 0.500 |
Why?
| | Adolescent | 31 | 2024 | 21574 | 0.500 |
Why?
| | Desensitization, Immunologic | 2 | 2018 | 96 | 0.490 |
Why?
| | Female | 58 | 2024 | 73465 | 0.480 |
Why?
| | Science | 1 | 2016 | 53 | 0.480 |
Why?
| | Laryngoscopy | 1 | 2016 | 109 | 0.480 |
Why?
| | Adaptation, Psychological | 2 | 2018 | 662 | 0.470 |
Why?
| | Research Report | 1 | 2015 | 83 | 0.460 |
Why?
| | Behavior Therapy | 1 | 2018 | 264 | 0.460 |
Why?
| | Pulmonary Medicine | 2 | 2016 | 86 | 0.460 |
Why?
| | Primary Health Care | 5 | 2021 | 1750 | 0.450 |
Why?
| | Surveys and Questionnaires | 15 | 2021 | 5793 | 0.450 |
Why?
| | Airway Obstruction | 1 | 2016 | 162 | 0.450 |
Why?
| | Telephone | 3 | 2020 | 173 | 0.450 |
Why?
| | Anxiety | 5 | 2016 | 1043 | 0.440 |
Why?
| | Sublingual Immunotherapy | 1 | 2014 | 5 | 0.440 |
Why?
| | Therapeutics | 1 | 2014 | 14 | 0.430 |
Why?
| | Diagnostic Techniques and Procedures | 1 | 2014 | 21 | 0.430 |
Why?
| | Pruritus | 4 | 2010 | 63 | 0.420 |
Why?
| | Clinical Trials as Topic | 2 | 2012 | 1052 | 0.420 |
Why?
| | Community-Institutional Relations | 1 | 2014 | 98 | 0.420 |
Why?
| | Quality of Health Care | 1 | 2018 | 642 | 0.410 |
Why?
| | Adult | 28 | 2023 | 38023 | 0.400 |
Why?
| | Motivational Interviewing | 1 | 2014 | 107 | 0.390 |
Why?
| | Family | 5 | 2022 | 671 | 0.380 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2014 | 157 | 0.380 |
Why?
| | Nebulizers and Vaporizers | 5 | 2023 | 86 | 0.380 |
Why?
| | Depression | 6 | 2018 | 1408 | 0.360 |
Why?
| | Organizational Affiliation | 1 | 2011 | 8 | 0.360 |
Why?
| | Behavioral Research | 1 | 2011 | 36 | 0.350 |
Why?
| | Child, Preschool | 14 | 2024 | 11105 | 0.350 |
Why?
| | Budesonide | 5 | 2012 | 89 | 0.350 |
Why?
| | Physical Therapy Modalities | 1 | 2014 | 308 | 0.340 |
Why?
| | Psychomotor Performance | 2 | 2004 | 309 | 0.340 |
Why?
| | Severity of Illness Index | 10 | 2019 | 2836 | 0.340 |
Why?
| | United States | 13 | 2021 | 14870 | 0.330 |
Why?
| | Reinforcement, Verbal | 1 | 2010 | 2 | 0.330 |
Why?
| | Socioeconomic Factors | 6 | 2022 | 1290 | 0.330 |
Why?
| | Art Therapy | 1 | 2010 | 20 | 0.330 |
Why?
| | Patient Participation | 2 | 2018 | 426 | 0.320 |
Why?
| | Histamine H1 Antagonists | 3 | 2005 | 30 | 0.310 |
Why?
| | Chronic Disease | 6 | 2018 | 1794 | 0.300 |
Why?
| | Curriculum | 1 | 2015 | 996 | 0.290 |
Why?
| | Health Services Accessibility | 2 | 2015 | 991 | 0.290 |
Why?
| | Pain | 1 | 2014 | 756 | 0.290 |
Why?
| | Critical Care | 3 | 2021 | 610 | 0.290 |
Why?
| | Focus Groups | 3 | 2011 | 530 | 0.280 |
Why?
| | Intensive Care Units | 1 | 2014 | 832 | 0.280 |
Why?
| | Middle Aged | 21 | 2020 | 33554 | 0.280 |
Why?
| | Cognition Disorders | 4 | 2014 | 496 | 0.280 |
Why?
| | Evidence-Based Medicine | 3 | 2021 | 740 | 0.280 |
Why?
| | Fluticasone | 4 | 2018 | 90 | 0.280 |
Why?
| | Sex Chromosome Aberrations | 3 | 2002 | 65 | 0.280 |
Why?
| | Technology | 2 | 2018 | 96 | 0.270 |
Why?
| | Health Literacy | 3 | 2021 | 168 | 0.260 |
Why?
| | Retrospective Studies | 7 | 2023 | 15682 | 0.260 |
Why?
| | Clinical Decision-Making | 2 | 2021 | 326 | 0.260 |
Why?
| | Sleep | 3 | 2008 | 755 | 0.250 |
Why?
| | Prednisone | 5 | 2022 | 242 | 0.250 |
Why?
| | Young Adult | 9 | 2022 | 13240 | 0.250 |
Why?
| | Albuterol | 1 | 2006 | 110 | 0.250 |
Why?
| | Rhinitis, Allergic, Perennial | 1 | 2005 | 23 | 0.240 |
Why?
| | Environmental Exposure | 2 | 2018 | 579 | 0.240 |
Why?
| | Guideline Adherence | 2 | 2021 | 556 | 0.230 |
Why?
| | Loratadine | 2 | 2004 | 4 | 0.230 |
Why?
| | Exercise | 1 | 2016 | 2061 | 0.230 |
Why?
| | Mood Disorders | 1 | 2006 | 133 | 0.230 |
Why?
| | Health Expenditures | 2 | 2016 | 189 | 0.220 |
Why?
| | Health Knowledge, Attitudes, Practice | 5 | 2016 | 1330 | 0.220 |
Why?
| | Data Collection | 1 | 2007 | 673 | 0.220 |
Why?
| | Qualitative Research | 2 | 2020 | 1399 | 0.220 |
Why?
| | Sleep Stages | 1 | 2004 | 47 | 0.210 |
Why?
| | Health Resources | 2 | 2016 | 121 | 0.210 |
Why?
| | Diphenhydramine | 2 | 2003 | 37 | 0.210 |
Why?
| | Colorado | 6 | 2020 | 4576 | 0.210 |
Why?
| | Salmeterol Xinafoate | 2 | 2018 | 41 | 0.210 |
Why?
| | Social Class | 2 | 2022 | 282 | 0.210 |
Why?
| | Histamine H1 Antagonists, Non-Sedating | 1 | 2003 | 1 | 0.210 |
Why?
| | Research | 3 | 2016 | 451 | 0.210 |
Why?
| | Nitric Oxide | 2 | 2019 | 915 | 0.200 |
Why?
| | Caregivers | 2 | 2016 | 888 | 0.200 |
Why?
| | Biomedical Research | 2 | 2021 | 700 | 0.200 |
Why?
| | Patient Dropouts | 1 | 2003 | 67 | 0.200 |
Why?
| | Risk-Taking | 1 | 2006 | 348 | 0.200 |
Why?
| | Hospitalization | 6 | 2020 | 2200 | 0.200 |
Why?
| | Overweight | 1 | 2007 | 558 | 0.200 |
Why?
| | Animals, Domestic | 1 | 2002 | 17 | 0.190 |
Why?
| | Age Factors | 6 | 2016 | 3305 | 0.180 |
Why?
| | Social Support | 4 | 2013 | 624 | 0.180 |
Why?
| | Emotions | 2 | 2018 | 551 | 0.180 |
Why?
| | Hypnotics and Sedatives | 2 | 2003 | 200 | 0.180 |
Why?
| | Income | 1 | 2022 | 203 | 0.180 |
Why?
| | Cost-Benefit Analysis | 2 | 2015 | 593 | 0.180 |
Why?
| | Tobacco Use | 1 | 2022 | 64 | 0.180 |
Why?
| | Health Services Needs and Demand | 1 | 2023 | 273 | 0.180 |
Why?
| | Thoracic Diseases | 1 | 2021 | 14 | 0.170 |
Why?
| | Disease Progression | 4 | 2024 | 2760 | 0.170 |
Why?
| | Nedocromil | 3 | 2009 | 32 | 0.170 |
Why?
| | Adolescent Behavior | 1 | 2006 | 531 | 0.170 |
Why?
| | Observational Studies as Topic | 1 | 2021 | 117 | 0.160 |
Why?
| | Smartphone | 2 | 2018 | 91 | 0.160 |
Why?
| | Models, Econometric | 1 | 2019 | 34 | 0.160 |
Why?
| | Behavior Control | 1 | 2019 | 13 | 0.160 |
Why?
| | Intelligence | 4 | 2007 | 123 | 0.150 |
Why?
| | Quality Improvement | 2 | 2019 | 1181 | 0.150 |
Why?
| | Telemetry | 1 | 2018 | 40 | 0.150 |
Why?
| | Allergists | 1 | 2018 | 12 | 0.150 |
Why?
| | Patient-Centered Care | 2 | 2016 | 530 | 0.150 |
Why?
| | Receptor, ErbB-4 | 1 | 2018 | 19 | 0.150 |
Why?
| | Prospective Studies | 7 | 2022 | 7623 | 0.150 |
Why?
| | Risk Factors | 8 | 2014 | 10407 | 0.140 |
Why?
| | Exhalation | 1 | 2018 | 39 | 0.140 |
Why?
| | Citalopram | 1 | 2018 | 29 | 0.140 |
Why?
| | Cloud Computing | 1 | 2017 | 7 | 0.140 |
Why?
| | Drug Monitoring | 1 | 2019 | 221 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2016 | 1478 | 0.140 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2018 | 45 | 0.140 |
Why?
| | Confidentiality | 1 | 2018 | 73 | 0.140 |
Why?
| | Health Plan Implementation | 1 | 2019 | 142 | 0.140 |
Why?
| | Patient Advocacy | 2 | 2020 | 76 | 0.140 |
Why?
| | Respiratory System | 1 | 2019 | 157 | 0.140 |
Why?
| | Medical Informatics | 1 | 2018 | 101 | 0.130 |
Why?
| | Respiratory Tract Diseases | 1 | 2018 | 184 | 0.130 |
Why?
| | Dry Powder Inhalers | 1 | 2016 | 2 | 0.130 |
Why?
| | Sleep Medicine Specialty | 1 | 2016 | 11 | 0.130 |
Why?
| | Health Surveys | 2 | 2009 | 514 | 0.130 |
Why?
| | Biosensing Techniques | 1 | 2018 | 129 | 0.130 |
Why?
| | Treatment Outcome | 9 | 2018 | 10837 | 0.130 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2018 | 323 | 0.130 |
Why?
| | Larynx | 1 | 2016 | 60 | 0.120 |
Why?
| | Respiration | 1 | 2016 | 199 | 0.120 |
Why?
| | Aged | 8 | 2019 | 24001 | 0.120 |
Why?
| | Time Factors | 2 | 2021 | 6834 | 0.120 |
Why?
| | Practice Guidelines as Topic | 4 | 2021 | 1586 | 0.120 |
Why?
| | Suicidal Ideation | 2 | 2012 | 534 | 0.120 |
Why?
| | Health Services | 1 | 2016 | 107 | 0.120 |
Why?
| | Health Education | 1 | 2018 | 341 | 0.120 |
Why?
| | Intention to Treat Analysis | 1 | 2015 | 73 | 0.120 |
Why?
| | Problem Behavior | 1 | 2016 | 103 | 0.110 |
Why?
| | Anti-Inflammatory Agents | 3 | 2010 | 496 | 0.110 |
Why?
| | Mental Disorders | 2 | 2014 | 1077 | 0.110 |
Why?
| | Pilot Projects | 3 | 2013 | 1713 | 0.110 |
Why?
| | Self Efficacy | 1 | 2018 | 396 | 0.110 |
Why?
| | Air Pollution | 1 | 2018 | 316 | 0.110 |
Why?
| | Depressive Disorder, Major | 1 | 2018 | 365 | 0.110 |
Why?
| | Psychology | 1 | 2014 | 85 | 0.110 |
Why?
| | Monosomy | 2 | 2004 | 12 | 0.110 |
Why?
| | Physicians | 1 | 2022 | 914 | 0.100 |
Why?
| | Community Health Services | 1 | 2015 | 227 | 0.100 |
Why?
| | Chromosomes, Human, X | 2 | 2004 | 74 | 0.100 |
Why?
| | Patient Acceptance of Health Care | 3 | 2015 | 807 | 0.100 |
Why?
| | Cost Savings | 1 | 2013 | 84 | 0.100 |
Why?
| | Pandemics | 1 | 2022 | 1639 | 0.100 |
Why?
| | Administration, Oral | 3 | 2018 | 816 | 0.100 |
Why?
| | Follow-Up Studies | 4 | 2014 | 5136 | 0.100 |
Why?
| | Turner Syndrome | 2 | 2004 | 54 | 0.100 |
Why?
| | Mobile Applications | 3 | 2024 | 183 | 0.100 |
Why?
| | Sex Factors | 3 | 2009 | 2077 | 0.100 |
Why?
| | Patient Reported Outcome Measures | 1 | 2016 | 403 | 0.100 |
Why?
| | Lung Diseases | 2 | 2016 | 767 | 0.100 |
Why?
| | Aged, 80 and over | 3 | 2016 | 7637 | 0.100 |
Why?
| | Referral and Consultation | 1 | 2018 | 786 | 0.100 |
Why?
| | Ethanolamines | 1 | 2012 | 17 | 0.100 |
Why?
| | Indians, North American | 1 | 2018 | 643 | 0.090 |
Why?
| | Self Report | 2 | 2019 | 829 | 0.090 |
Why?
| | Primary Prevention | 1 | 2013 | 196 | 0.090 |
Why?
| | Multimedia | 1 | 2011 | 10 | 0.090 |
Why?
| | Program Evaluation | 2 | 2019 | 901 | 0.090 |
Why?
| | Equipment Design | 3 | 2020 | 522 | 0.090 |
Why?
| | Thinking | 1 | 2012 | 65 | 0.090 |
Why?
| | Emergency Service, Hospital | 2 | 2021 | 2072 | 0.090 |
Why?
| | Amygdala | 2 | 2004 | 191 | 0.090 |
Why?
| | Needs Assessment | 1 | 2013 | 376 | 0.090 |
Why?
| | Longitudinal Studies | 4 | 2007 | 2860 | 0.090 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2018 | 2189 | 0.080 |
Why?
| | Sickness Impact Profile | 1 | 2010 | 56 | 0.080 |
Why?
| | Immunotherapy | 1 | 2015 | 641 | 0.080 |
Why?
| | Odds Ratio | 3 | 2009 | 1070 | 0.080 |
Why?
| | Drug Therapy, Combination | 3 | 2012 | 1067 | 0.080 |
Why?
| | Forced Expiratory Volume | 3 | 2013 | 531 | 0.080 |
Why?
| | Patient Satisfaction | 3 | 2022 | 665 | 0.080 |
Why?
| | Interdisciplinary Communication | 1 | 2010 | 191 | 0.080 |
Why?
| | Continuity of Patient Care | 1 | 2011 | 284 | 0.080 |
Why?
| | Comorbidity | 1 | 2014 | 1623 | 0.080 |
Why?
| | Program Development | 1 | 2011 | 368 | 0.070 |
Why?
| | Activity Cycles | 1 | 2008 | 5 | 0.070 |
Why?
| | Peer Group | 2 | 2013 | 243 | 0.070 |
Why?
| | Cooperative Behavior | 1 | 2011 | 452 | 0.070 |
Why?
| | Beclomethasone | 1 | 2008 | 27 | 0.070 |
Why?
| | Infant | 3 | 2021 | 9482 | 0.070 |
Why?
| | Cohort Studies | 4 | 2013 | 5750 | 0.070 |
Why?
| | Affect | 2 | 2014 | 292 | 0.070 |
Why?
| | Inflammation | 1 | 2019 | 2838 | 0.070 |
Why?
| | Incidence | 2 | 2014 | 2804 | 0.070 |
Why?
| | Patients | 1 | 2009 | 175 | 0.070 |
Why?
| | Animals | 4 | 2018 | 36951 | 0.070 |
Why?
| | Self Disclosure | 1 | 2007 | 63 | 0.070 |
Why?
| | Computers | 1 | 2007 | 70 | 0.070 |
Why?
| | Smoking | 2 | 2007 | 1627 | 0.070 |
Why?
| | Monitoring, Ambulatory | 1 | 2008 | 87 | 0.070 |
Why?
| | Schools | 1 | 2010 | 462 | 0.070 |
Why?
| | Social Isolation | 1 | 2007 | 62 | 0.070 |
Why?
| | Polysomnography | 1 | 2008 | 185 | 0.070 |
Why?
| | Culture | 1 | 2008 | 128 | 0.070 |
Why?
| | Cocaine-Related Disorders | 1 | 2007 | 113 | 0.060 |
Why?
| | Practice Patterns, Physicians' | 1 | 2015 | 1313 | 0.060 |
Why?
| | Child Behavior Disorders | 1 | 2007 | 144 | 0.060 |
Why?
| | Double-Blind Method | 2 | 2018 | 1997 | 0.060 |
Why?
| | Infant, Newborn | 2 | 2016 | 6084 | 0.060 |
Why?
| | Attention | 2 | 2007 | 427 | 0.060 |
Why?
| | Self-Assessment | 2 | 2003 | 72 | 0.060 |
Why?
| | Attitude to Health | 1 | 2009 | 439 | 0.060 |
Why?
| | Family Practice | 1 | 2010 | 464 | 0.060 |
Why?
| | Health Status | 1 | 2010 | 792 | 0.060 |
Why?
| | Monocytes | 1 | 2008 | 563 | 0.060 |
Why?
| | Neuropsychological Tests | 2 | 2007 | 1025 | 0.060 |
Why?
| | Software | 1 | 2010 | 665 | 0.060 |
Why?
| | Logistic Models | 3 | 2010 | 2075 | 0.060 |
Why?
| | Marijuana Abuse | 1 | 2007 | 233 | 0.060 |
Why?
| | Societies, Medical | 2 | 2021 | 820 | 0.060 |
Why?
| | Health Care Sector | 1 | 2004 | 25 | 0.050 |
Why?
| | Parent-Child Relations | 2 | 2004 | 272 | 0.050 |
Why?
| | Memory, Short-Term | 1 | 2007 | 252 | 0.050 |
Why?
| | Suicide, Attempted | 1 | 2007 | 382 | 0.050 |
Why?
| | Administration, Intranasal | 1 | 2004 | 90 | 0.050 |
Why?
| | Drug Costs | 1 | 2005 | 107 | 0.050 |
Why?
| | Allergy and Immunology | 1 | 2024 | 43 | 0.050 |
Why?
| | Interleukin-6 | 1 | 2008 | 778 | 0.050 |
Why?
| | Poverty | 2 | 2020 | 521 | 0.050 |
Why?
| | Drug Utilization | 2 | 2018 | 169 | 0.050 |
Why?
| | Patient Care | 1 | 2004 | 111 | 0.050 |
Why?
| | Self Administration | 1 | 2003 | 123 | 0.050 |
Why?
| | Tacrolimus | 1 | 2004 | 200 | 0.050 |
Why?
| | Temporal Lobe | 1 | 2003 | 91 | 0.050 |
Why?
| | Drug Industry | 1 | 2004 | 111 | 0.050 |
Why?
| | Safety | 1 | 2005 | 338 | 0.050 |
Why?
| | Mass Screening | 2 | 2011 | 1288 | 0.050 |
Why?
| | Sensitivity and Specificity | 3 | 2019 | 1946 | 0.050 |
Why?
| | Motor Activity | 1 | 2007 | 718 | 0.050 |
Why?
| | Regression Analysis | 2 | 2016 | 1024 | 0.050 |
Why?
| | X Chromosome | 1 | 2002 | 53 | 0.050 |
Why?
| | Diagnostic Tests, Routine | 1 | 2003 | 110 | 0.050 |
Why?
| | Genetic Counseling | 1 | 2002 | 77 | 0.050 |
Why?
| | Mosaicism | 1 | 2002 | 73 | 0.050 |
Why?
| | Aneuploidy | 1 | 2002 | 90 | 0.040 |
Why?
| | Activities of Daily Living | 1 | 2005 | 413 | 0.040 |
Why?
| | Hippocampus | 2 | 2004 | 895 | 0.040 |
Why?
| | Smoking Prevention | 1 | 2002 | 184 | 0.040 |
Why?
| | Italy | 1 | 2021 | 110 | 0.040 |
Why?
| | Social Behavior | 1 | 2003 | 287 | 0.040 |
Why?
| | Health Care Costs | 1 | 2004 | 398 | 0.040 |
Why?
| | Alcohol Drinking | 1 | 2007 | 828 | 0.040 |
Why?
| | Cost of Illness | 1 | 2003 | 308 | 0.040 |
Why?
| | Prenatal Diagnosis | 1 | 2002 | 201 | 0.040 |
Why?
| | Cytokines | 1 | 2008 | 2085 | 0.040 |
Why?
| | Global Burden of Disease | 1 | 2019 | 24 | 0.040 |
Why?
| | Electronics | 1 | 2020 | 76 | 0.040 |
Why?
| | Patient Selection | 1 | 2003 | 696 | 0.040 |
Why?
| | Developmental Disabilities | 1 | 2002 | 264 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2004 | 894 | 0.040 |
Why?
| | Case-Control Studies | 3 | 2019 | 3569 | 0.040 |
Why?
| | Artificial Intelligence | 1 | 2022 | 282 | 0.040 |
Why?
| | Body Mass Index | 1 | 2007 | 2390 | 0.040 |
Why?
| | Datasets as Topic | 1 | 2019 | 121 | 0.040 |
Why?
| | Homozygote | 1 | 2018 | 203 | 0.040 |
Why?
| | Placebos | 1 | 2018 | 199 | 0.030 |
Why?
| | Safety-net Providers | 1 | 2019 | 119 | 0.030 |
Why?
| | Morbidity | 1 | 2018 | 324 | 0.030 |
Why?
| | Drug Administration Schedule | 2 | 2011 | 786 | 0.030 |
Why?
| | Organizational Policy | 1 | 2016 | 84 | 0.030 |
Why?
| | Insurance Claim Review | 1 | 2016 | 64 | 0.030 |
Why?
| | Diffusion of Innovation | 1 | 2016 | 100 | 0.030 |
Why?
| | Intelligence Tests | 2 | 2007 | 57 | 0.030 |
Why?
| | Cognition | 1 | 2003 | 1157 | 0.030 |
Why?
| | Wounds and Injuries | 1 | 2002 | 760 | 0.030 |
Why?
| | Prevalence | 1 | 2002 | 2734 | 0.030 |
Why?
| | Education | 1 | 2015 | 108 | 0.030 |
Why?
| | Vital Capacity | 2 | 2009 | 314 | 0.030 |
Why?
| | MP3-Player | 1 | 2013 | 2 | 0.030 |
Why?
| | Philadelphia | 1 | 2013 | 49 | 0.030 |
Why?
| | Phenotype | 1 | 2002 | 3196 | 0.030 |
Why?
| | United Kingdom | 1 | 2014 | 318 | 0.030 |
Why?
| | Lung | 2 | 2023 | 4060 | 0.020 |
Why?
| | Memory | 1 | 2014 | 248 | 0.020 |
Why?
| | Demography | 2 | 2004 | 291 | 0.020 |
Why?
| | Formoterol Fumarate | 1 | 2012 | 7 | 0.020 |
Why?
| | Medical Records | 2 | 2003 | 177 | 0.020 |
Why?
| | Interview, Psychological | 1 | 2011 | 96 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 2013 | 601 | 0.020 |
Why?
| | Psychometrics | 2 | 2007 | 720 | 0.020 |
Why?
| | Models, Organizational | 1 | 2011 | 151 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2018 | 1172 | 0.020 |
Why?
| | Urban Population | 1 | 2013 | 479 | 0.020 |
Why?
| | Models, Psychological | 1 | 2011 | 301 | 0.020 |
Why?
| | Reproducibility of Results | 2 | 2008 | 3290 | 0.020 |
Why?
| | Pregnancy | 1 | 2002 | 6771 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2004 | 2057 | 0.020 |
Why?
| | Emergency Medical Services | 1 | 2015 | 552 | 0.020 |
Why?
| | Body Height | 1 | 2009 | 199 | 0.020 |
Why?
| | Emergencies | 1 | 2009 | 164 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2008 | 431 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2007 | 53 | 0.020 |
Why?
| | False Positive Reactions | 1 | 2007 | 115 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 3 | 2004 | 3577 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 2007 | 187 | 0.010 |
Why?
| | Models, Statistical | 1 | 2009 | 669 | 0.010 |
Why?
| | Child Behavior | 1 | 2007 | 248 | 0.010 |
Why?
| | Internet | 1 | 2009 | 655 | 0.010 |
Why?
| | Educational Status | 1 | 2007 | 470 | 0.010 |
Why?
| | Administration, Topical | 1 | 2004 | 151 | 0.010 |
Why?
| | Language Disorders | 1 | 2003 | 30 | 0.010 |
Why?
| | Cross-Sectional Studies | 2 | 2007 | 5478 | 0.010 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2003 | 30 | 0.010 |
Why?
| | Dogs | 1 | 2003 | 413 | 0.010 |
Why?
| | Matched-Pair Analysis | 1 | 2002 | 39 | 0.010 |
Why?
| | Appointments and Schedules | 1 | 2002 | 89 | 0.010 |
Why?
| | Karyotyping | 1 | 2002 | 104 | 0.010 |
Why?
| | Age of Onset | 1 | 2003 | 520 | 0.010 |
Why?
| | Motor Skills | 1 | 2002 | 97 | 0.010 |
Why?
| | Immunoglobulin E | 1 | 2003 | 345 | 0.010 |
Why?
| | Disclosure | 1 | 2002 | 113 | 0.010 |
Why?
| | Outpatients | 1 | 2004 | 397 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2004 | 1316 | 0.010 |
Why?
| | Forecasting | 1 | 2002 | 389 | 0.010 |
Why?
| | Growth | 1 | 2000 | 60 | 0.010 |
Why?
| | Guidelines as Topic | 1 | 2002 | 275 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2003 | 1509 | 0.010 |
Why?
| | Skin | 1 | 2004 | 752 | 0.010 |
Why?
|
|
Bender's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|